Northwire Canada EditionFriday, July 24, 2026
Sign inSubscribe
Northwire
⌕
AVX 0.005 −nan% AII 19.91 −1.0% GWM 0.480 +0.0% GEN 0.065 +0.0% NIO 0.135 −3.6% III 7.22 −2.8% NCAU 0.295 −3.3% NEV 0.040 +0.0% ITR 3.00 −1.6% ALDE 2.79 −0.7% TECK 84.18 +4.4% FVI 11.83 −2.2% SUM 1.31 −1.5% RSMX 0.115 +4.5% STW 0.105 +5.0% PAT 0.250 +0.0% AVX 0.005 −nan% AII 19.91 −1.0% GWM 0.480 +0.0% GEN 0.065 +0.0% NIO 0.135 −3.6% III 7.22 −2.8% NCAU 0.295 −3.3% NEV 0.040 +0.0% ITR 3.00 −1.6% ALDE 2.79 −0.7% TECK 84.18 +4.4% FVI 11.83 −2.2% SUM 1.31 −1.5% RSMX 0.115 +4.5% STW 0.105 +5.0% PAT 0.250 +0.0%
Regulatory

Quantum BioPharma Files Reply and Provides Update on Court Case Seeking Damages Against CIBC, RBC and Others in Excess of $700,000,000 USD for Possible Stock Price Manipulation/Spoofing

By The Northwire Desk — AI Analysis Aug 04, 2025 · 07:33 QNTM · 32.75 Quantum BioPharma Ltd.
QNTM · Price

Executive Summary

  • Quantum BioPharma filed a memorandum of law in opposition to a joint motion to dismiss filed by defendants CIBC World Markets and RBC Dominion Securities in the U.S. District Court for the Southern District of New York.
  • The underlying lawsuit alleges that the defendants engaged in market manipulation schemes, specifically "spoofing," between January 1, 2020, and August 15, 2024, in violation of the Securities Exchange Act of 1934.
  • Quantum BioPharma is seeking damages exceeding $700 million USD, alleging that the manipulation artificially depressed the company's stock price, which traded over $460 USD per share in January 2020.

Key Details

  • Legal Filing: Memorandum of Law in opposition to defendants' motion to dismiss, filed on July 31, 2025.
  • Defendants: CIBC World Markets and RBC Dominion Securities (jointly).
  • Allegations: The Amended Complaint (filed May 31, 2025) alleges violations of Section 10(b) and Rule 10b-5(a) and (c) and Section 9(a) of the Securities Exchange Act of 1934.
  • Specific Conduct: Defendants allegedly used "spoofing" techniques hundreds of times to manipulate the share price of Quantum BioPharma.
  • Damages Sought: More than $700 Million USD.
  • Timeframe of Alleged Manipulation: January 1, 2020, to August 15, 2024.
  • Stock Performance Context: The company states its stock traded over $460 USD per share (adjusted for splits) in January 2020, with a market cap approaching $1 billion.
  • Legal Representation: The case is being handled on a contingency basis by law firms Christian Attar and Freedman Normand Friedland LLP, meaning there is no material financial pressure on the Company to bear legal costs.
  • Additional Suspects: The Company believes other banks/brokers are involved but will not name them until more conclusive evidence is gathered.
  • Resolution Stance: The Company remains open to dialogue and an amicable solution with the involved banks and brokers.

Notable Quotes

  • "Quantum is seeking damages of more than $700 Million USD."
  • "The complaint details this evidence, which the Company alleges demonstrates that Defendants 'spoofed' the market hundreds of times, thereby artificially depressing the price of the Company’s stock repeatedly, resulting in harm both the Company and its investors."
Read the original news release →

More from Quantum BioPharma Ltd.

Jun 26, 2026 · 08:30

Preclinical MS drug developer navigating FDA clinical hold while leveraging consumer supplement royalties.

Other Jun 25, 2026 · 08:30

Pre-revenue MS developer navigates FDA clinical hold while doubling down on myelin-repair narrative and consumer-health royalties

Other Jun 24, 2026 · 08:30

A pre-revenue biotech touting an MS drug's potential while its lead IND sits on clinical hold and the company stays silent on the setback in its latest marketing push.

Other Jun 22, 2026 · 08:30

Pre-revenue MS drug developer navigating FDA hold and negative equity while pursuing a $700M manipulation lawsuit.

Other Jun 01, 2026 · 19:30

A clinical hold on its lead MS drug and the sudden exit of a key director deal a double blow to Quantum BioPharma, erasing near-term catalysts and raising red flags about governance and data quality.

Regulatory May 18, 2026 · 03:00

Quantum BioPharma’s MS study hits halfway mark with early positive imaging signals, but the real catalyst remains an imminent FDA greenlight for its Phase 2 trial.

Other